Literature DB >> 24361081

Present state of Japanese cedar pollinosis: the national affliction.

Takechiyo Yamada1, Hirohisa Saito2, Shigeharu Fujieda3.   

Abstract

Seasonal allergic rhinitis (SAR) caused by Japanese cedar pollen (JCP; ie, sugi-pollinosis) is the most common disease in Japan and has been considered a national affliction. More than one third of all Japanese persons have sugi-pollinosis, and this number has significantly increased in the last 2 decades. In our opinion the reason why sugi-pollinosis became a common disease in the last half century is the increased number of cedar pollens, with global climate change and forest growth caused by the tree-planting program of the Japanese government after World War II playing substantial roles; dust storms containing small particulate matter from China might also contribute to the increased incidence of sugi-pollinosis. To help minimize their symptoms, many Japanese wear facemasks and eyeglasses at all times between February and April to prevent exposure to JCP and aerosol pollutants. Forecasts for JCP levels typically follow the weather forecast in mass media broadcasts, and real-time information regarding JCP levels is also available on the Internet. Because a large amount of JCP is produced over several months, it can induce severe symptoms. Japanese guidelines for allergic rhinitis recommend prophylactic treatment with antihistamines or antileukotrienes before the start of JCP dispersion. Additionally, sublingual immunotherapy will be supported by health insurance in the summer of 2014. However, many patients with sugi-pollinosis do not find satisfactory symptom relief with currently available therapies. Collaboration between scientists and pharmaceutical companies to produce new therapeutics for the control of sugi-pollinosis symptoms is necessary.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Japanese cedar; Seasonal allergic rhinitis; alternative complementary treatments; global climate change; prophylactic treatment

Mesh:

Substances:

Year:  2013        PMID: 24361081     DOI: 10.1016/j.jaci.2013.11.002

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  41 in total

1.  Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects.

Authors:  Tetsuya Terada; Masaya Matsuda; Miki Inaba; Junpei Hamaguchi; Naoki Takemoto; Yusuke Kikuoka; Yuko Inaka; Harumi Sakae; Kennosuke Hashimoto; Hayato Shimora; Kazuyuki Kitatani; Ryo Kawata; Takeshi Nabe
Journal:  Inflamm Res       Date:  2021-04-09       Impact factor: 4.575

2.  Inhibition of an Allergen-Antibody Reaction Related to Japanese Cedar Pollinosis Using DNA Aptamers Against the Cry j 2 Allergen.

Authors:  Kazumasa Ogihara; Nasa Savory; Koichi Abe; Wataru Yoshida; Mitsuru Arakawa; Masahiko Asahi; Seika Kamohara; Kazunori Ikebukuro
Journal:  Nucleic Acid Ther       Date:  2015-10-20       Impact factor: 5.486

3.  Immunodominance in allergic T-cell reactivity to Japanese cedar in different geographic cohorts.

Authors:  Carla Oseroff; John Pham; April Frazier; Denise Hinz; John Sidney; Sinu Paul; Jason A Greenbaum; Randi Vita; Bjoern Peters; Véronique Schulten; Alessandro Sette
Journal:  Ann Allergy Asthma Immunol       Date:  2016-12       Impact factor: 6.347

Review 4.  Next generation immunotherapy for tree pollen allergies.

Authors:  Yan Su; Eliezer Romeu-Bonilla; Teri Heiland
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

5.  Inhibitory effect of Japanese black vinegar on IgE-mediated degranulation of RBL-2H3 cells and a murine model of Japanese cedar pollinosis.

Authors:  Seiji Awane; Kosuke Nishi; Momoko Ishida; Masanobu Nagano; Kazunori Hashiguchi; Akira Fujii; Takuya Sugahara
Journal:  Cytotechnology       Date:  2018-03-02       Impact factor: 2.058

6.  Intranasal exposure to monoclonal antibody Fab fragments to Japanese cedar pollen Cry j1 suppresses Japanese cedar pollen-induced allergic rhinitis.

Authors:  S Yoshino; N Mizutani
Journal:  Br J Pharmacol       Date:  2016-04-06       Impact factor: 8.739

7.  Transcutaneous Peptide Immunotherapy of Japanese Cedar Pollinosis Using Solid-in-Oil Nanodispersion Technology.

Authors:  Momoko Kitaoka; Yoko Shin; Noriho Kamiya; Yoshinori Kawabe; Masamichi Kamihira; Masahiro Goto
Journal:  AAPS PharmSciTech       Date:  2015-05-19       Impact factor: 3.246

Review 8.  Probiotics, their prophylactic and therapeutic applications in human health development: A review of the literature.

Authors:  Bantayehu Addis Tegegne; Bekalu Kebede
Journal:  Heliyon       Date:  2022-06-22

9.  Effectiveness and safety of allergen immunotherapy in patients with allergic rhinitis complicated by rheumatic autoimmune diseases: a case series study.

Authors:  Kazuki Fujioka; Akiko Kasahara; Takashi Kida; Wataru Fujii; Takahiro Seno; Makoto Wada; Masataka Kohno; Yutaka Kawahito
Journal:  Allergy Asthma Clin Immunol       Date:  2022-07-11       Impact factor: 3.373

10.  Association between Mouth Breathing and Atopic Dermatitis in Japanese Children 2-6 years Old: A Population-Based Cross-Sectional Study.

Authors:  Harutaka Yamaguchi; Saaya Tada; Yoshinori Nakanishi; Shingo Kawaminami; Teruki Shin; Ryo Tabata; Shino Yuasa; Nobuhiko Shimizu; Mitsuhiro Kohno; Atsushi Tsuchiya; Kenji Tani
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.